Handbook of Parkinson's Disease Therapeutics

Rosario Moratalla is a Professor of Neuroscience, Director of the Center of Interdisciplinary Research and Vice-Chair at the Cajal Institute, Consejo Superior de Investigaciones Científicas, Madrid. Dr. Moratalla‘s research interests lie on the dopaminergic system and its role in drug abuse and Parkinson’s disease. She is interested in the molecular mechanisms that modulate cellular responses in the basal ganglia motor circuit, in the context of Parkinson’s disease, L-DOPA-induced dyskinesia and impulse control disorders and drug abuse. In relationship with Parkinson's disease, her studies intend to determine the neurobiological correlates of dyskinesias induced by antiparkinsonian therapy, as well as to establish the neuronal circuits involved in non-motor symptoms of Parkinson’s disease. Gustavo Murer is Professor and Chair of the Institute of Physiology and Biophysics "Bernardo Houssay" at the University of Buenos Aires School of Medicine. Dr. Murer is an expert on the functional alterations that take place in the basal ganglia in Parkinson's disease and other basal ganglia related disorders. His research focuses on the electrophysiological and morphological alterations that take place in the striatum in animal models of Parkinson's disease. His recent investigations examine how chronic dopamine depletion and dopamine replacement therapy produce changes in the activity of basal ganglia neurons, which molecular mechanisms underlie these changes, and how they modify basal ganglia function and behavior.

• 1. History, milestones in PD and antiparkinsonian therapy research2. Basal ganglia anatomy3. Models of BG functional organization and their relevance to PD and antiparkinsonian therapy4. PD diagnosis, motor symptoms and their pharmacological management5. Non-motor symptoms and their pharmacological management6. The prodromal phase of PD; prediction of diagnosis and prevention7. Complications of L-DOPA therapy and their management8. Neuropsychological spectrum symptoms in Parkinson disease9. Impact of serotonergic system in L-DOPA therapeutic effect in PD10. REM sleep behavior disorder and PD11. Deep Brain Stimulation and other Functional Neurosurgery Approaches12. Gene therapy and other promising new therapies13. The search of a disease modifying treatments for PD14. Magnetic resonance guided-focused ultrasound in Parkinson’s disease15. Healthcare innovations and patient centered collaborative care in PD16. non-invasive brain stimulation for freezing of gait and other PD symptoms non responsive to L-dopa17. Imaging of nigrostriatal system/other systems/other biomarkers18. Animal models for the study of PD pathophysiology and the predictive validity of treatments19. Functional synaptic plasticity in PD and changes induced by antiparkinsonian therapy20. Structural synaptic plasticity in PD and changes induced by antiparkinsonian therapy21. Interventions on direct and indirect pathways with effects on motor symptoms and dyskinesia22. Role of the GP in PD symptoms and therapeutics